Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Cell Biochem ; 477(12): 2817-2828, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35666430

RESUMO

Pancreatic inflammation and oxidative damage remain major concerns in type 1 diabetes mellitus (T1DM). Punicalagin, a major polyphenol in pomegranates, exhibited antioxidant and protective effects on several organs in case of T1DM; however, no study has yet explored the protective effects of punicalagin on the pancreas and islets of Langerhans. T1DM was induced by injecting 40 mg/kg streptozotocin (STZ) intraperitoneally. Punicalagin (1 mg/kg ip) was injected daily for 15 days after T1DM induction. In diabetic rats, punicalagin treatment lowered the levels of inflammatory biomarkers (monocyte chemoattractant protein-1 and C-reactive protein) and adhesion molecules (E-selectin, intercellular adhesion molecule, and vascular cell adhesion molecule) while activating myeloperoxidase activity. Treatment of diabetic rats with punicalagin improved glutathione content and superoxide dismutase, catalase, and glutathione peroxidase activities; upregulated serum paraoxonase-1 activity; and prevented the elevation lipid peroxidation and protein oxidation products in the pancreas. Furthermore, punicalagin protected the pancreas against STZ-induced histopathological alterations and increased immune-reactive ß-cells while reducing leucocyte infiltration into the islets of Langerhans, leading to normalized blood glucose and insulin levels. These findings indicated that punicalagin might protect against the development of insulitis in T1DM. In conclusion, punicalagin exerts a strong protective effect on the pancreas against oxidative injury and inflammation in STZ-induced experimental T1DM. The present results recommend punicalagin as a potential adjuvant for reducing diabetes-associated insulitis.


Assuntos
Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 1 , Ratos , Animais , Diabetes Mellitus Tipo 1/patologia , Diabetes Mellitus Experimental/metabolismo , Estresse Oxidativo , Estreptozocina/efeitos adversos , Antioxidantes/farmacologia , Antioxidantes/metabolismo , Glicemia/metabolismo , Inflamação/tratamento farmacológico , Inflamação/prevenção & controle , Insulina/metabolismo
2.
Toxicol Ind Health ; 32(9): 1537-49, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25537623

RESUMO

Epidemiological reports have indicated a correlation between the increasing bisphenol A (BPA) levels in the environment and the incidence of male infertility. In this study, the protective effects of melatonin on BPA-induced oxidative stress and apoptosis were investigated in the rat testes and epididymal sperm. Melatonin (10 mg/kg body weight (bw)) was injected concurrently with BPA (50 mg/kg bw) for 3 and 6 weeks. The administration of BPA significantly increased oxidative stress in the testes and epididymal sperm. This was associated with a decrease in the serum testosterone level as well as sperm quality, chromatin condensation/de-condensation level, and the percentage of haploid germ cells in the semen. BPA administration caused a significant increase in apoptosis accompanied by a decrease in the expression of the antiapoptotic proteins Bcl-2 in the testes and epididymal sperm. The concurrent administration of melatonin decreased oxidative stress by modulating the levels of glutathione, superoxide dismutase, and catalase as well as the malondialdehyde and hydrogen peroxide concentrations in the testes and sperm. Melatonin sustained Bcl-2 expression and controlled apoptosis. Furthermore, melatonin maintained the testosterone levels, ameliorated histopathological changes, increased the percentages of seminal haploid germ cells, and protected sperm chromatin condensation process, indicating appropriate spermatogenesis with production of functional sperm. In conclusion, melatonin protected against BPA-induced apoptosis by controlling Bcl-2 expression and ameliorating oxidative stress in the testes and sperm. Thus, melatonin is a promising pharmacological agent for preventing the potential reproductive toxicity of BPA following occupational or environmental exposures.


Assuntos
Antioxidantes/uso terapêutico , Apoptose/efeitos dos fármacos , Compostos Benzidrílicos/toxicidade , Suplementos Nutricionais , Disruptores Endócrinos/toxicidade , Melatonina/uso terapêutico , Fenóis/toxicidade , Testículo/efeitos dos fármacos , Animais , Compostos Benzidrílicos/antagonistas & inibidores , Montagem e Desmontagem da Cromatina/efeitos dos fármacos , Disruptores Endócrinos/química , Poluentes Ambientais/antagonistas & inibidores , Poluentes Ambientais/toxicidade , Epididimo/efeitos dos fármacos , Epididimo/metabolismo , Epididimo/patologia , Infertilidade Masculina/sangue , Infertilidade Masculina/induzido quimicamente , Infertilidade Masculina/metabolismo , Infertilidade Masculina/prevenção & controle , Masculino , Estresse Oxidativo/efeitos dos fármacos , Fenóis/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-bcl-2/agonistas , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Distribuição Aleatória , Ratos Sprague-Dawley , Análise do Sêmen , Espermatogênese/efeitos dos fármacos , Espermatogônias/efeitos dos fármacos , Espermatogônias/metabolismo , Espermatogônias/patologia , Testículo/metabolismo , Testículo/patologia , Testosterona/sangue , Testosterona/metabolismo , Vacúolos/efeitos dos fármacos , Vacúolos/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...